Depomed acquisition makes strategic sense, says JMP Securities

After Depomed announced that it had acquired migraine treatment CAMBIA, JMP Securities thinks that the deal leverages the company’s established neurology-focused sales organization. The firm raised its price target on the stock to $11 from $10 and reiterates an Outperform rating on the shares.